XenoGesis Overview

  • Founded
  • 2011
  • Status
  • Private
  • Employees
  • 18
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $141K
Latest Deal Amount
  • Investors
  • 4

XenoGesis General Information


Provider of advising and laboratory-based research services intended to assist pharmaceutical clients engaged in drug discovery. The company's services specialize in preclinical metabolism, pharmacokinetics, quantitative bio-analysis and expert interpretation, enabling clients to get iterative feedback from the research team based on the results obtained by their researches.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Consulting Services (B2B)
Other Healthcare Services
Primary Office
  • BioCity Nottingham
  • Pennyfoot Street, Nottinghamshire
  • Nottingham NG1 1GF
  • England, United Kingdom
+44 0115 000 0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XenoGesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 29-Jan-2020 $141K 00000 Completed Generating Revenue
1. Early Stage VC 06-Mar-2012 00000 00000 00000 Completed Generating Revenue
To view XenoGesis’s complete valuation and funding history, request access »

XenoGesis Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 0000.00 0000.00 00 0000.00 00.000
To view XenoGesis’s complete cap table history, request access »

XenoGesis Executive Team (4)

Name Title Board Seat Contact Info
Richard Weaver Ph.D Founder, Board Member & Managing Director
Dawn Parkins Founding Member & Director, Operations
Manfred Ismair Ph.D Transporter Expert
John Dixon Ph.D Board Member, Drug Discovery Advisor & Business Development
To view XenoGesis’s complete executive team members history, request access »

XenoGesis Board Members (2)

Name Representing Role Since
Glenn Crocker Ph.D Mobius Life Sciences Fund Board Member 000 0000
John Dixon Ph.D Self Board Member, Drug Discovery Advisor & Business Development 000 0000
To view XenoGesis’s complete board members history, request access »

XenoGesis Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XenoGesis Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Nottingham City Council Corporation 000 0000 000000 0
University of Derby Corporation 000 0000 000000 0
BioCity Accelerator/Incubator Minority 000 0000 000000 0
Mobius Life Sciences Fund Venture Capital Minority 000 0000 000000 0
To view XenoGesis’s complete investors history, request access »